By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

OncoGenex Technologies Inc. 

400 - 1001 West Broadway

Vancouver  B.C.  V6H 4B1  Canada
Phone: 604-736-3678 Fax: 604-736-3687


SEARCH JOBS


Industry
Biotechnology






Company News
FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 8/22/2008 6:23:42 AM
Sonus Pharmaceuticals, Inc. (SNUS) and OncoGenex Technologies Inc. Complete Business Combination 8/21/2008 8:10:20 AM
Sonus Pharmaceuticals, Inc. (SNUS)'s Stockholders Approve Business Combination With OncoGenex Technologies Inc. 8/20/2008 6:17:24 AM
OncoGenex Technologies Inc. Receives Completed Special Protocol Assessment for Primary Registration Study of Lead Drug Candidate OGX-011 7/14/2008 6:17:56 AM
OncoGenex Technologies Inc. Increases Economic Interest in Lead Cancer Drug OGX-011 7/3/2008 6:33:44 AM
Isis Pharmaceuticals, Inc. (ISIS)' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology 6/2/2008 11:22:52 AM
OncoGenex Technologies Inc. Reports That Low Serum Clusterin Levels Were Predictive Of Survival In Preliminary Analyses Of Phase 2 Study Of Lead Drug Candidate OGX-011 Encouraging Survival Duration Continues With OGX-011 Plus Second-Line Chemotherapy For The Treatment Of Prostate Cancer; Data Presented At The 2008 Annual Meeting Of The American Society of Clinical Oncology 6/2/2008 9:43:37 AM
Sonus Pharmaceuticals, Inc. (SNUS) and OncoGenex Technologies Inc. to Merge 5/28/2008 6:35:01 AM
OncoGenex Technologies Inc. Reports Updated Survival Data on OGX-011 in a Second-line Chemotherapy Trial for Patients with Prostate Cancer Updated Data to be Presented at the 2008 Annual Meeting of the American Society of Clinical Oncology 5/16/2008 12:03:49 PM
OncoGenex Technologies Inc. Reports Lead Drug Candidate OGX-011 Achieved Primary Endpoint in Phase 2 Trial 2/15/2008 6:20:03 AM
1234
//-->